RGC Earnings & Financial Statements
Regencell Bioscience Holdings Limited
$5.21
-$0.42(-7.38%)
36
Overall
40
Value
27
Tech
42
Quality
Market Cap
$2.58B
Volume
77.73K
52W Range
$4.51 - $69.00
Target Price
--
RGC earnings and financial statements: Regencell Bioscience Holdings Limited's income statement, balance sheet and cash flow statement, annual and quarterly.
RGC Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating income | -$11.72M | -$3.77M | -$4.74M | -$6.27M | -$7.62M |
| EBITDA | -$11.30M | -$3.19M | -$3.62M | -$5.29M | -$7.01M |
| Net income | -$11.70M | -$3.58M | -$4.42M | -$5.87M | -$7.45M |
| EPS (diluted) | $-0.02 | $-0.01 | $-0.87 | $-0.45 | $-0.58 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $14.73M | $5.76M | $8.44M | $12.62M | $18.02M |
| Total liabilities | $1.38M | $895.3K | $219.5K | $632.3K | $938.0K |
| Shareholders’ equity | $13.35M | $4.86M | $8.22M | $12.03M | $17.07M |
| Cash and equivalents | $14.19M | $2.42M | $2.96M | $1.56M | $6.42M |
| Long-term debt | $59.5K | $231.6K | $25.9K | $25.4K | $360.3K |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.70M | -$3.11M | -$4.00M | -$4.96M | -$5.27M |
| Capital expenditure | - | - | - | - | -$780.9K |
| Free cash flow | -$7.70M | -$3.27M | -$4.01M | -$4.99M | -$6.05M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RGC | $5.21 | -7.4% | 77.73K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Regencell Bioscience Holdings Limited Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW